---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-23-004444"
form_type: "8-K"
ticker: "BCRX"
cik: "0000882796"
company_name: "BIOCRYST PHARMACEUTICALS INC"
filed_at: "2023-07-11T23:59:59+00:00"
generated_at: "2026-06-13T10:23:56.215017+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# BioCryst principal accounting officer resigns; CFO to serve as interim

## Summary
- Michael Jones, Principal Accounting Officer, resigns effective July 7, 2023; will stay as Exec. Director Finance through April 2024.
- Resignation not due to any disagreement on company operations, policies, or practices.
- Board appoints CFO Anthony Doyle as interim Principal Accounting Officer effective July 10, 2023.
- Doyle's compensation unchanged; no family relationships or transactions disclosed.

## SEC filing metadata
- accession: 0001171843-23-004444
- form_type: 8-K
- ticker: BCRX
- cik: 0000882796
- company_name: BIOCRYST PHARMACEUTICALS INC
- filed_at: 2023-07-11T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/882796/000117184323004444/0001171843-23-004444-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/882796/000117184323004444/f8k_071123.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-23-004444
- JSON: https://secwatch.observer/filing/0001171843-23-004444.json
- Plain text: https://secwatch.observer/filing/0001171843-23-004444.txt

## Key facts
- Executive change
  Anthony Doyle was appointed as Interim Principal Accounting Officer at BIOCRYST PHARMACEUTICALS INC.
  - Action: appointed
  - Role: Interim Principal Accounting Officer
  source text: On July 10, 2023, the Board of Directors of the Company appointed Anthony Doyle, the Company’s Chief Financial Officer, to serve as interim Principal Accounting Officer, effective as of the same date.
  evidence_url: https://www.sec.gov/Archives/edgar/data/882796/000117184323004444/0001171843-23-004444-index.htm
- Executive change
  Michael L. Jones resigned as Principal Accounting Officer at BIOCRYST PHARMACEUTICALS INC.
  - Action: resigned
  - Role: Principal Accounting Officer
  source text: On July 7, 2023, Michael L. Jones, Executive Director, Finance and Principal Accounting Officer of BioCryst Pharmaceuticals, Inc. (the “Company”), informed the Company of his intention to resign from the Company.
  evidence_url: https://www.sec.gov/Archives/edgar/data/882796/000117184323004444/0001171843-23-004444-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.